Tom Wiggans, Pardes Biosciences CEO
April 3, 2023 11:44 AM EDT
R&D
Coronavirus

Biotech launched dur­ing Covid — for Covid — looks for strate­gic al­ter­na­tives af­ter an­tivi­ral fails PhII tri­al

Amber Tong

Senior Editor

A next-gen Covid-19 an­tivi­ral has flunked a Phase II test, forc­ing its de­vel­op­er to go in­to some se­ri­ous soul search­ing.

The mid-stage read­out was cru­cial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times